Search Results for: uploads

Download the PDF SAN JUAN CAPISTRANO, CA — September 25, 2023 — Allegro Ophthalmics, LLC, a privately held biopharmaceutical company focused on the development of novel mitochondrial stabilizers for the treatment of ocular diseases, today announced that its licensee, AffaMed Therapeutics, has received Clinical Trial Application (CTA) approval from China’s National Medical Products Administration to […]

Download the PDF Intermediate Dry AMD Treatment Is a Significant Unmet Need Mitochondrial Stabilizing Candidate Risuteganib Has Shown Best Corrected Visual Acuity Gains in Dry AMD Patient Population SAN JUAN CAPISTRANO, CA — April 12, 2023 — Allegro Ophthalmics, LLC, a privately held biopharmaceutical company focused on the development of novel mitochondrial stabilizers for the […]

Download the PDF Intermediate Dry AMD Treatment Highlighted as Significant Unmet Need Only Mitochondrial Stabilizing Candidates, Including Allegro’s Risuteganib, Have Shown Best Corrected Visual Acuity (BCVA) Gains in this Patient Population SAN JUAN CAPISTRANO, CA — February 10, 2023 — Allegro Ophthalmics, LLC, a privately held biopharmaceutical company focused on the development of novel oxidative […]

Download the PDF SAN JUAN CAPISTRANO, CA — April 27, 2022 — Allegro Ophthalmics, LLC, a privately held biopharmaceutical company focused on the development of novel oxidative stress stabilizers for the treatment of ocular diseases, today announced that two scientific posters involving risuteganib, the company’s lead investigational compound in retina, will be presented during the […]

Download the PDF SAN JUAN CAPISTRANO, CA — August 3, 2021 — Allegro Ophthalmics, LLC, a privately held biopharmaceutical company focused on the development of novel oxidative stress stabilizers for the treatment of ocular diseases, today announced that the results of the company’s U.S. Phase 2a risuteganib non-exudative age-related macular degeneration (dry AMD) study are published […]

Download the PDF Allegro also announces FDA acceptance of IND for ALG-1007 for dry eye disease, clearing path to initiate Phase 2b/3 U.S. study SAN JUAN CAPISTRANO, CA — July 24, 2021 — Allegro Ophthalmics, LLC, a privately held biopharmaceutical company focused on the development of novel oxidative stress stabilizers for the treatment of ocular […]

Download the PDF Marks Allegro’s Second Exploratory Study of ALG-1007 in Dry Eye Disease SAN JUAN CAPISTRANO, CA — July 19, 2021 — Allegro Ophthalmics, LLC, a privately held biopharmaceutical company focused on the development of novel oxidative stress-stabilizers for the treatment of ocular diseases, today announced that the results of the company’s second ALG-1007 ex-U.S. […]

Download the PDF Executive Team Strengthened with the Appointment of Stephanie Yee as Vice President of Finance SAN JUAN CAPISTRANO, CA — June 22, 2021 — Allegro Ophthalmics, LLC, a privately held biopharmaceutical company focused on the development of novel integrin-regulating therapies for the treatment of ocular diseases, today announced that William J. Link, PhD, […]

Download the PDF SAN JUAN CAPISTRANO, CA — April 27, 2021 — Allegro Ophthalmics, LLC, a privately held biopharmaceutical company focused on the development of novel integrin regulating therapies for the treatment of ocular diseases, today announced that four scientific posters involving risuteganib, the company’s lead investigational compound in retina, will be presented during the […]

Agreement Includes Global Rights for Risuteganib, An Investigational Treatment Expected to Help Reverse Vision Loss Due to Dry AMD, A Significant Unmet Medical Need Download the PDF LAVAL, Quebec, and San Juan Capistrano, Calif., Sept. 21, 2020 – Bausch Health Companies Inc. (NYSE/TSX: BHC) (“Bausch Health”) and Bausch + Lomb, its leading global eye health business, […]